Table 1.
Baseline characteristics of the study population according to the genotypes for the rs700518 polymorphism
| GG (N=24) | GA+AA (N=81) | *P | |
|---|---|---|---|
|
| |||
| Age (yrs) | 62.7±6.4 | 60.1±9.1 | 0.27 |
|
| |||
| BMI (kg/m2) | 29.4±6.6 | 31.1±7.8 | 0.41 |
|
| |||
| YSM | 12.7±9.1 | 13.0±11.0 | 0.89 |
|
| |||
| Positive smoking history | 38.9% | 21.3% | 0.19 |
|
| |||
| Aromatase inhibitor used | 0.65 | ||
| a) Anastrozole | 15 | 47 | |
| b) Letrozole | 3 | 8 | |
| c) Exemestane | 1 | 8 | |
|
| |||
| Patients with chemotherapy | 2/18 (11.1%) | 28/64 (43.8%) | 0.009 |
|
| |||
| Fat mass index (kg/m2) | 12.52±3.98 | 12.30±4.45 | 0.83 |
|
| |||
| Trunk fat mass index(kg/m2) | 6.02±2.16 | 5.71±2.48 | 0.58 |
|
| |||
| Fat-free mass index (kg/m2) | 18.48±2.60 | 18.62±2.65 | 0.82 |
|
| |||
| Estradiol (pg/ml) | 14.16±8.16 | 12.65±4.60 | 0.31 |
Values are Means±SD; BMI: body mass index, YSM: years since menopause,
*
P T-test for age, BMI, and YSM; analysis of covariance adjusted for age for other continuous variables; chi-square for categorical variables